Home Newsfeeds Barclays Maintains Overweight on Arvinas, Lowers Price Target to $70

Barclays Maintains Overweight on Arvinas, Lowers Price Target to $70

Barclays analyst Peter Lawson maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target from $90 to $70.

byBenzinga Newsdesk

November 23, 2022

1 minute read

Barclays analyst Peter Lawson maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target from $90 to $70.

Stage Set For Generics As Biden Admin Asks Supreme Court To Hear Skinny Labels Case Between GSK, Teva

By Vandana Singh

March 31, 10:10 AM

The Biden Administration told the U.S. Supreme Court that it should agree to hear a patent appeal over…

GSK

Events
News

Reported Late Thursday March 30, Australian Prime Minister Anthony Albanese Visits Tritium At The Company’s Campus In Brisbane, Australia

By Happy Mohamed

March 31, 12:26 AM

Tritium DCFC Limited (Tritium) (NASDAQ:DCFC), a global leader in direct current (DC) fast chargers for electric vehicles (EVs), welcomed Australian Prime Minister Anthony Albanese to the company's campus in

DCFC

Data Analytics Software Firm Alteryx In Privatization Talks Amid Intense Competition, Valuation Challenges

By Vandana Singh

December 15, 10:04 AM

A private equity consortium comprising Insight Partners and Clearlake Capital Group is currently engaged in advanced negotiations to take the data analytics software company Alteryx Inc (NYSE: AYX) private for roughly $5 billion, including debt, R

AYX

NewAmsterdam Pharma Reports 9-Month Revenue Of $13.3M, 9- Month EPS Of $(1.55)

By Benzinga Newsdesk

November 13, 9:31 AM

Financial HighlightsCash Position: As of September 30, 2023, NewAmsterdam recorded cash of $368.3 million (€347.7 million), compared to $467.7 million (€438.5 million) as of December 31, 2022. The decrease reflects cash

NAMS

Barclays Maintains Overweight on Arvinas, Lowers Price Target to $70

Related Posts

Stage Set For Generics As Biden Admin Asks Supreme Court To Hear Skinny Labels Case Between GSK, Teva

Reported Late Thursday March 30, Australian Prime Minister Anthony Albanese Visits Tritium At The Company’s Campus In Brisbane, Australia

Data Analytics Software Firm Alteryx In Privatization Talks Amid Intense Competition, Valuation Challenges

NewAmsterdam Pharma Reports 9-Month Revenue Of $13.3M, 9- Month EPS Of $(1.55)